You are here

Home

Clinical Trials: Liver Disease

Each Clinical Trial will open in a new browser window or tab.

Return to Clinical Trials Page

Posted: Tuesday, March 30, 2021 - 12:00
Safety of UC-MSC Transfusion for ACLF Patients
Condition:   Acute-On-Chronic Liver Failure
Intervention:   Genetic: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)
Sponsor:   Hai Li
Not yet recruiting
Posted: Friday, February 19, 2021 - 12:00
Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease
Condition:   Fatty Liver, Nonalcoholic
Interventions:   Drug: Cilostazol 50 MG;   Drug: Placebo
Sponsor:   Sadat City University
Recruiting
Posted: Wednesday, February 17, 2021 - 12:00
Muscles in Liver Diseases
Condition:   Patients Having a Scheduled Abdominal Surgery Procedure
Interventions:   Other: blood samples;   Other: biopsy of abdominal paroie
Sponsor:   Assistance Publique - Hôpitaux de Paris
Not yet recruiting
Posted: Wednesday, April 22, 2020 - 12:00
Umbilical Cord Mesenchymal Stem Cell for Liver Cirrhosis Patient Caused by Hepatitis B
Condition:   Liver Cirrhoses
Intervention:   Biological: Allogeneic Umbilical Cord Mesenchymal Stem Cell
Sponsor:   PT. Prodia Stem Cell Indonesia
Recruiting
Posted: Tuesday, January 28, 2020 - 12:00
Combination of Autologous MSC and HSC Infusion in Patients With Decompensated Cirrhosis
Condition:   Cirrhosis, Liver
Interventions:   Combination Product: CD 34 and MSC infusion;   Drug: Standard of care for Cirrhosis management
Sponsor:   Asian Institute of Gastroenterology, India
Recruiting
Posted: Thursday, September 12, 2019 - 12:00
A Phase II Open-label Single-arm Study to Evaluate the Efficacy and Safety of Autologous Adipose-derived Stem Cells (ADSCs) in Subjects With Liver Cirrhosis
Condition:   Liver Cirrhosis
Intervention:   Drug: GXHPC1
Sponsor:   Gwo Xi Stem Cell Applied Technology Co., Ltd.
Not yet recruiting
Posted: Monday, May 27, 2019 - 12:00
Safety and Tolerability of HepaStem in Patients With Cirrhotic and Pre-cirrhotic NASH Patients
Condition:   NASH - Nonalcoholic Steatohepatitis
Intervention:   Drug: HepaStem
Sponsor:   Promethera Biosciences
Recruiting
Posted: Tuesday, May 21, 2019 - 12:00
Safety and Efficacy of SHED for Decompensated Liver Cirrhosis
Condition:   Liver Cirrhosis
Interventions:   Biological: 2 times SHED group;   Biological: 4 times SHED group
Sponsors:   Changhai Hospital;   Eastern Hepatobiliary Surgery Hospital;   CAR-T (Shanghai) Biotechnology Co., Ltd.
Not yet recruiting
Posted: Friday, May 10, 2019 - 12:00
Mesenchymal Stem Cells Treatment for Decompensated Liver Cirrhosis
Condition:   Decompensated Liver Cirrhosis
Interventions:   Biological: umbilical cord-derived mesenchymal stem cell;   Other: Comprehensive treatment
Sponsor:   Beijing 302 Hospital
Recruiting
Posted: Friday, March 1, 2019 - 12:00
Allogeneic ABCB5-positive Stem Cells for Treatment of Acute-on-Chronic Liver Failure
Condition:   Acute-On-Chronic Liver Failure
Intervention:   Biological: allo-APZ2-ACLF
Sponsors:   RHEACELL GmbH & Co. KG;   FGK Clinical Research GmbH;   Ticeba GmbH
Not yet recruiting

Pages